Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties
D. Dobre
(1, 2)
,
J. S. Borer
(3)
,
K. Fox
(4)
,
K. Swedberg
(5)
,
K. F. Adams
(6)
,
J. G. Cleland
(7)
,
A. Cohen-Solal
(8, 9)
,
M. Gheorghiade
(10)
,
François Gueyffier
(11, 12)
,
C. M. O'Connor
(13)
,
M. Fiuzat
(13)
,
A. Patak
(14)
,
I. L. Pina
(15)
,
G. Rosano
(16)
,
H. N. Sabbah
(17)
,
L. Tavazzi
(18)
,
F. Zannad
(1, 2)
1
Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]
2 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
3 SUNY - State University of New York
4 NHLI - National Heart and Lung Institute
5 GU - Göteborgs Universitet = University of Gothenburg
6 UNC - University of North Carolina [Chapel Hill]
7 University of Hull [United Kingdom]
8 Inserm U942 - Service de Biochimie et de Biologie Moléculaire [AP-HP Hôpital Lariboisière]
9 UPD7 - Université Paris Diderot - Paris 7
10 [Northwestern University Medical School] - Feinberg School of Medicine [Northwestern University, Evanston]
11 HCL - Hospices Civils de Lyon
12 Evaluation et modélisation des effets thérapeutiques [LBBE]
13 Duke University [Durham]
14 Equipe 8 - Déterminants moléculaires et cliniques de l'architecture cardiaque
15 Albert Einstein College of Medicine [New York]
16 IRCCS San Raffaele Pisana - Istituto di Ricovero e Cura a Carattere Scientifico
17 Henry Ford Hospital
18 Maria Cecilia Hospital
2 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
3 SUNY - State University of New York
4 NHLI - National Heart and Lung Institute
5 GU - Göteborgs Universitet = University of Gothenburg
6 UNC - University of North Carolina [Chapel Hill]
7 University of Hull [United Kingdom]
8 Inserm U942 - Service de Biochimie et de Biologie Moléculaire [AP-HP Hôpital Lariboisière]
9 UPD7 - Université Paris Diderot - Paris 7
10 [Northwestern University Medical School] - Feinberg School of Medicine [Northwestern University, Evanston]
11 HCL - Hospices Civils de Lyon
12 Evaluation et modélisation des effets thérapeutiques [LBBE]
13 Duke University [Durham]
14 Equipe 8 - Déterminants moléculaires et cliniques de l'architecture cardiaque
15 Albert Einstein College of Medicine [New York]
16 IRCCS San Raffaele Pisana - Istituto di Ricovero e Cura a Carattere Scientifico
17 Henry Ford Hospital
18 Maria Cecilia Hospital
François Gueyffier
- Fonction : Auteur
- PersonId : 178661
- IdHAL : francois-gueyffier
- ORCID : 0000-0002-9921-0977
- IdRef : 091433061
Résumé
Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (risk factor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bradycardic agent.